Table 3.
Efficacy in phase Ib expansion
| Ia escalation | Ib expansion | |||
|---|---|---|---|---|
| IBI110 monotherapy (n = 28) | IBI110 plus sintilimab (n = 43)* | sqNSCLC cohort (n = 20) | GC cohort (n = 17) | |
| Confirmed Best Overall Response, n (%) | ||||
| Partial response(PR) | 1 (3.6) | 3 (7.0) | 15 (75.0) | 12 (70.6) |
| Stable disease(SD) | 6 (21.4) | 26 (60.5) | 2 (10.0) | 4 (23.5) |
| Progressive disease(PD) | 21 (75.0) | 14 (32.6) | 3 (15.0) | 1 (5.9) |
| unconfirmed ORR, % (95% CI) | 3.6% (0-10.5) | 14.0% (3.6–24.3) | 80.0% (56.3–94.3) | 88.2% (63.6–98.5) |
| confirmed ORR, % (95% CI) | 3.6% (0-10.5) | 7.0% (0-14.6) | 75.0% (50.9–91.3) | 70.6% (44.0-89.7) |
| DCR, % (95% CI) | 25.0% (9.0–41.0) | 67.4% (53.4–81.5) | 85.0% (62.1–96.8) | 94.1% (71.3–99.9) |
*43 of 45 patients in phase Ib combination dose escalation had undergone at least 1 post-baseline tumor assessment as of the cutoff date